Summit Therapeutics SMMT

Jump To Section

    $

    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    .
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    -$0.22 (-0.82%)Past DayToday's Volume:
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0

    Relative Strength Index (RSI)

    - The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

    - The RSI is calculated using the following formula:

    RSI = 100 - (100 / (1 + RS))

    Where RS is the ratio of the average gains to the average losses over a specified period.

    - The default time period used is 14 days.

    - RSI values range between 0 and 100.

    RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

    RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

    RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

    About

    Summit Therapeutics (SMMT) Business Model and Operations Summary
    Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.

    Key Insights

    Summit Therapeutics (SMMT) Core Market Data and Business Metrics
    • Latest Closing Price

      $26.74
    • Market Cap

      $15.14 Billion
    • Average Daily Volume

      4,750,193 Shares
    • 52-Week Range

      $6.78-$36.91
    • Price-Earnings Ratio

      -76.40
    • Total Outstanding Shares

      742.67 Million Shares
    • CEO

      Mr. Robert W. Duggan
    • Total Employees

      159
    • Current Dividend

      No dividend
    • IPO Date

      March 5, 2015
    • SIC Description

      Pharmaceutical Preparations
    • Headquarters

      601 Brickell Key Drive, Miami, FL, 33131

    Earnings Reports

    Expected vs. Actual Quarterly Earnings-Per-Share & Revenue

    Short Volume

    Daily short volume activity identifies short-term trading pressure and potential price volatility

    Short Interest

    Bi-monthly short interest levels can be used to gauge bearish market sentiment and short squeeze potential

    Revenue Breakdown

    Distribution of revenue across unique business segments & geographies

    Cash Flow Statement

    April 1, 2024 to March 31, 2025

    Income Statement

    April 1, 2024 to March 31, 2025

    Comprehensive Income

    April 1, 2024 to March 31, 2025

    Balance Sheet

    April 1, 2024 to March 31, 2025

    Historical Stock Splits

    Historical Dividends

    Recent Headlines From The Web

    Latest news, press releases, and media coverage about SMMT from trusted financial sources

    Related Companies

    Publicly traded companies similar to Summit Therapeutics (SMMT)
    Boost your savings and earn 3.95% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.